Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFatigue is one of the most commonly reported experiences in the first weeks of Mounjaro treatment, yet it catches many people off guard. If you feel unusually tired after starting tirzepatide, you are not alone, and in most cases the exhaustion has a straightforward explanation rooted in how the medicine works. These are prescription-only medicines assessed and prescribed for weight management following a clinical consultation; a prescriber weighs your individual picture before and during treatment. Understanding why fatigue happens — and when it deserves closer attention — makes a real difference to how you manage it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misconception our prescribers hear is that deep tiredness in the first few weeks signals that something has gone wrong, or that the medicine is the wrong choice. In reality, almost the opposite is true. Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, that are involved in appetite regulation and metabolic signalling. When these pathways shift, the body is doing something genuinely new. Fatigue during that adjustment is a sign of physiological change, not failure.
The NHS tirzepatide information page lists tiredness alongside nausea and dizziness as known side effects, most prominent after starting treatment or stepping to a higher dose. That matters because it frames fatigue as an expected feature of the adjustment window rather than a red flag. For the majority of people, energy levels stabilise within two to three weeks. The tiredness that feels overwhelming in week two tends to feel manageable by week five.
If you want a fuller picture of how tirzepatide works in the body, our tirzepatide overview covers the dual-agonist mechanism in plain language. What it means in practice is that your body is recalibrating its relationship with hunger signals, gastric emptying, and blood-sugar regulation all at once. A degree of tiredness during that recalibration is not unusual. It is not, however, something to simply push through indefinitely without support.
A question our prescribers hear most weeks is: "I'm not even nauseous, so why am I so tired?" The answer is that fatigue on Mounjaro rarely has a single cause. Several things tend to happen in parallel during the first weeks, and they compound.
Calorie intake drops, often sharply, because appetite suppression is one of the medicine's central effects. The body is used to a certain fuel load; when that drops quickly, energy levels follow. This is especially noticeable if protein intake falls alongside total calories, because protein supports muscle function and sustained energy. On top of this, gastric emptying slows, meaning food moves through the stomach more gradually. That is useful for appetite control, but it can leave people feeling sluggish or heavy after meals in a way that reads as tiredness.
Gastrointestinal side effects (nausea, loose stools, or poor appetite) can also lead to mild dehydration, which amplifies fatigue considerably. Even a small fluid deficit makes physical and cognitive effort feel disproportionately hard. If you have experienced any of the common early side effects of Mounjaro, the dehydration piece is worth taking seriously. Aim for consistent water intake across the day rather than trying to catch up in one go.
Some people also notice that their sleep is slightly disrupted in early treatment, particularly if nausea is worse in the evening. Poor sleep quality feeds directly into daytime fatigue in a way that can look like a medicine problem when it is actually a sleep problem with a fixable cause.
The adjustment period is real, but it is manageable for most people with a few deliberate habits. These are not substitutes for clinical advice; they are the sort of practical suggestions that complement what your prescriber recommends.
Protein is the most important dietary factor. Aiming for adequate protein at each meal (rather than simply eating less of everything) helps preserve energy and muscle function during the early weeks. The NHS's healthy weight guidance notes that diet quality matters alongside any weight-management intervention, and protein adequacy is central to that on a reduced-calorie pattern.
Hydration is the second priority. Drink water consistently through the day, not just when you feel thirsty. If gastrointestinal symptoms have been present, replace fluids more deliberately. Some people find cold or sparkling water easier on a sensitive stomach.
Gentle movement tends to help more than rest on its own. A short walk often improves energy better than lying down, counterintuitive as that sounds. Heavy exercise in the first few weeks, however, can deplete energy reserves when intake is already lower than usual; balance matters.
For context on what a supervised treatment pathway looks like, and how our clinical team supports patients through the adjustment phase, take a look at our weight-loss treatment overview. Support during the early weeks is part of what distinguishes a properly managed prescription from an unreviewed one.
Most fatigue on Mounjaro is benign and time-limited. Some is not, and knowing the difference matters. Contact your prescriber or GP promptly if exhaustion is severe enough to affect daily functioning and is not improving after two to three weeks, if it arrives alongside significant dizziness or fainting, or if it is accompanied by severe stomach pain that spreads to the back. The MHRA flagged acute pancreatitis as a known but infrequent serious side effect of GLP-1 medicines in its January 2026 Drug Safety Update; abdominal pain of that character alongside profound fatigue deserves urgent medical attention rather than a wait-and-see approach.
Extreme cold sensitivity alongside tiredness is worth mentioning to your prescriber too. You can read more about that specific combination on our page covering feeling cold on Mounjaro, which looks at the physiological reasons that symptom pair can occur. Similarly, if unusual warmth or hot flushes accompany your tiredness, our page on feeling hot on Mounjaro covers those experiences. If you are curious how others describe their experience of feeling exhausted on Mounjaro, that page brings together real-world accounts alongside clinical context that can help you gauge whether what you are experiencing is typical. Symptoms rarely arrive in isolation.
You can report suspected side effects directly to the MHRA through the Yellow Card scheme at any time. This is separate from contacting your clinical team and supports broader safety monitoring of the medicine; both steps are worth taking if a side effect concerns you.
If you are considering whether Mounjaro is right for your circumstances, or want to understand what a clinical assessment involves, you can read about how Lottie Moss has spoken about her own Mounjaro journey for a patient perspective before you check your eligibility through a free consultation with our GPhC-registered prescribers, who review every case personally.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.